Search results for Labetuzumab

Labetuzumab Biosimilar – Anti-CEACAM5 mAb – Research Grade, ProteoGenix, PX-TA1048

Description of Labetuzumab Biosimilar - Anti-CEACAM5 mAb - Research Grade Introduction Labetuzumab Biosimilar, also known as Anti-CEACAM5 mAb, is a monoclonal antibody that has been developed as a biosimilar to the original Labetuzumab. This antibody specifically targets the carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), which is overexpressed in various types of cancer. In this article, we will discuss the structure, activity, and potential applications of Labetuzumab Biosimilar in the field of cancer research. Structure of Labetuzumab Biosimilar Labetuzumab Biosimilar is a recombinant, humanized IgG1 monoclonal antibody that has been engineered to have a similar structure to the original Labetuzumab. It consists of two heavy chains and two light chains, connected by disulfide bonds. The heavy chains contain constant regions (Fc) and variable regions (Fab), while the light chains contain only variable regions. The variable regions are responsible for binding to the target antigen, CEACAM5, while the constant regions are involved in effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Activity of Labetuzumab Biosimilar Labetuzumab Biosimilar binds specifically to CEACAM5, a glycoprotein that is overexpressed in a variety of cancers, including colorectal, pancreatic, and lung cancer. This binding inhibits the growth and spread of cancer cells by blocking the interaction between CEACAM5 and its ligands, which are involved in cell adhesion and signaling pathways. Additionally, Labetuzumab Biosimilar can induce ADCC and CDC, leading to the destruction of cancer cells by the immune system. Potential Applications of Labetuzumab Biosimilar Labetuzumab Biosimilar has shown promising results in preclinical and clinical studies as a potential therapeutic agent for various types of cancer. Here are some potential applications of this antibody: 1. Treatment of Colorectal Cancer CEACAM5 is highly expressed in colorectal cancer cells, making it an ideal target for Labetuzumab Biosimilar. In a phase II clinical trial, Labetuzumab Biosimilar showed promising results in combination with chemotherapy in patients with metastatic colorectal cancer. It significantly improved progression-free survival and overall survival compared to chemotherapy alone. 2. Treatment of Pancreatic Cancer Pancreatic cancer is one of the most aggressive and difficult-to-treat cancers. CEACAM5 is overexpressed in pancreatic cancer cells, and Labetuzumab Biosimilar has shown efficacy in preclinical studies. A phase I clinical trial is currently ongoing to evaluate the safety and efficacy of Labetuzumab Biosimilar in combination with chemotherapy in patients with advanced pancreatic cancer. 3. Treatment of Lung Cancer CEACAM5 is also overexpressed in lung cancer cells, and Labetuzumab Biosimilar has shown promising results in preclinical studies. A phase II clinical trial is currently ongoing to evaluate the safety and efficacy of Labetuzumab Biosimilar in combination with chemotherapy in patients with advanced non-small cell lung cancer. 4. Research Tool for Cancer Studies In addition to its potential therapeutic applications, Labetuzumab Biosimilar can also serve as a valuable research tool for studying the role of CEACAM5 in cancer development and progression. It can be used in various techniques such as flow cytometry, immunohistochemistry, and Western blotting to detect and quantify CEACAM5 expression in cancer cells. Conclusion Labetuzumab Biosimilar is a promising biosimilar of the original Labetuzumab, with a similar structure and activity. Its specific targeting of CEACAM5, a protein overexpressed in various types of cancer, makes it a potential therapeutic agent for colorectal, pancreatic, and lung cancer. Furthermore, it can also serve as a valuable research tool for studying the role of CEACAM5 in cancer. Further clinical trials are needed to fully evaluate the efficacy and safety of Labetuzumab Biosimilar, but it holds great

Labetuzumab, Abbexa, abx831014

Labetuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CEACAM5, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Labetuzumab is a humanized monoclonal antibody to carcinoembryonic antigen that inhibits tumor growth. It is used in radioimmunotherapy.

Labetuzumab ELISA Kit, ProteoGenix, KPTX154

Description of Labetuzumab ELISA Kit The Structure of Labetuzumab ELISA Kit Labetuzumab ELISA Kit is a highly specific and sensitive diagnostic tool used for the detection and quantification of Labetuzumab, a monoclonal antibody used as a therapeutic target for various types of cancer. The kit is designed to measure the levels of Labetuzumab in biological samples such as serum, plasma, and cell culture supernatants. The kit contains all the necessary components for a sandwich enzyme-linked immunosorbent assay (ELISA) test, including pre-coated microplates, Labetuzumab-specific antibodies, and enzyme-conjugated secondary antibodies. The microplates are coated with a highly purified and specific Labetuzumab capture antibody, which is able to bind to the target antigen with high affinity and specificity. The Activity of Labetuzumab ELISA Kit The Labetuzumab ELISA Kit utilizes the principle of sandwich ELISA, which involves the use of two different antibodies that bind to different epitopes on the target antigen. The first antibody, the capture antibody, is immobilized on the surface of the microplate and is able to capture the target antigen from the sample. The second antibody, the detection antibody, is conjugated to an enzyme and is able to bind to a different epitope on the target antigen. The captured antigen is then detected by the enzyme-conjugated detection antibody, which produces a measurable signal when it comes into contact with a substrate. The intensity of the signal is directly proportional to the amount of Labetuzumab present in the sample, allowing for accurate quantification of the target antigen. The Application of Labetuzumab ELISA Kit Labetuzumab ELISA Kit has a wide range of applications in the field of cancer research and drug development. It is primarily used for the detection and quantification of Labetuzumab in clinical samples, making it a valuable tool for monitoring the effectiveness of Labetuzumab-based therapies. The kit can also be used for the screening and characterization of Labetuzumab in cell culture supernatants and other biological samples. This allows for the identification of potential therapeutic candidates and the optimization of production processes for Labetuzumab. Furthermore, Labetuzumab ELISA Kit can be used in preclinical studies to evaluate the pharmacokinetics and pharmacodynamics of Labetuzumab. This information is crucial for the development of new Labetuzumab-based therapies and for the determination of appropriate dosages for clinical trials. In addition to its applications in research and drug development, Labetuzumab ELISA Kit can also be used in clinical settings for the diagnosis and monitoring of Labetuzumab-responsive cancers, such as colorectal cancer and pancreatic cancer. The kit provides a quick, accurate, and cost-effective method for measuring Labetuzumab levels, allowing for early detection and personalized treatment plans for patients. Conclusion In summary, Labetuzumab ELISA Kit is a highly specialized and sensitive diagnostic tool that plays a crucial role in the detection, quantification, and monitoring of Labetuzumab in various biological samples. Its unique sandwich ELISA design and high specificity make it a valuable tool for cancer research, drug development, and clinical applications. With its ability to accurately measure Labetuzumab levels, this kit has the potential to improve patient outcomes and contribute to the development of new and effective therapies for Labetuzumab-responsive cancers.

Labetuzumab ELISA Kit, Abbexa, abx395043

Labetuzumab ELISA Kit is a quantitative ELISA kit for detection of Labetuzumab.

Labetuzumab Biosimilar - Research Grade, ichor.bio, ICH5120

Detects human CEACAM5

Research Grade Labetuzumab (HY546016), abinScience, HY546016

Labetuzumab Govitecan Biosimilar - Research Grade, ichor.bio, ICH5617G